New allelic arrangement CYP2D6*36 x 2 found in a Japanese poor metabolizer of debrisoquine

Pharmacogenetics

Volumn 12, Issue 8, 2002, Pages 659-662

  Chida, Michihiro ^a   Ariyoshi, Noritaka ^a,e   Yokoi, Tsuyoshi ^a   Nemoto, Nobuo ^b   Inaba, Makoto ^c   Kinoshita, Moritoshi ^d   Kamataki, Tetsuya ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c CANCER CHEMOTHERAPY CENTER   (Japan)

^d OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^e CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CYP2D6* 10; Gene duplication; Genotype

Indexed keywords

CYTOCHROME P450 2D6; DEBRISOQUINE;

ALLELE; ARTICLE; DRUG METABOLISM; GENE DUPLICATION; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; JAPAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ALLELES; BASE SEQUENCE; CYTOCHROME P-450 CYP2D6; DEBRISOQUIN; DNA PRIMERS; GENOTYPE; HUMANS; POLYMERASE CHAIN REACTION;

EID: 0036866855     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200211000-00011     Document Type: Article

References (10)

1. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6:193-201.
2. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: Analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991; 8:545-558.
3. Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjöqvist F. Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992; 51:12-17.
4. Chida M, Yokoi T, Kosaka Y, Chiba K, Nakamura H, Ishizaki T, et al. Genetic polymorphism of CYP2D6 in the Japanese population. Pharmacogenetics 1999; 9:601-605.
5. Tateishi T, Chida M, Ariyoshi N, Mizorogi M, Kamataki T, Kobayashi S. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther 1999; 65:570-575.
6. Yokoi T, Kosaka Y, Chida M, Chiba K, Nakamura H, Ishizaki T, et al. A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype. Pharmacogenetics 1996; 6:395-401.
7. Chida M, Yokoi T, Nemoto N, Inaba M, Kinoshita M, Kamataki T. A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype. Pharmacogenetics 1999; 9:287-293.
8. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: Sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 1989; 45:889-904.
9. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994; 46:252-259.
10. Fukuda T, Nishida Y, Imaoka S, Hiroi T, Naohara M, Funae Y, et al. The decreased in vivo clearance of CYP2D6 substrates by CYP2D6* 10 might be caused not only by the low expression but also by low affinity of CYP2D6. Arch Biochem Biophys 2000; 380:303-308.